In summary, we have generated rhCD137L-MSN, a CD137 agonist with an improved therapeutic potential that allows effective tumor control, while circumventing the hepatotoxicity often observed with agonistic anti-CD137 antibodies. Here, TNFRSF9 is linked to neoplasm.